XPhyto Therapeutics Corp.

Recent News

  • XPhyto Provides Update on Parkinsons' Transdermal Patch

    Vancouver, British Columbia--(Newsfile Corp. - August 25, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) ("XPhyto" or the "Company"), a next generation bioscience company, is pleased to announce an update on its transdermal delivery system ("TDS") for the neurologic drug Rotigotine. Further to the Company's press release dated, June 8, 2020, regarding formula finalization, Vektor Pharma TF GmbH ("Vektor"), a wholly owned German subsidiary of XPhyto, has now completed process implementation for the manufacture of its Rotigotine...

    2020-08-25 3:05 AM EDT
  • XPhyto Therapeutics Corp.: COVID-19 Rapid Screening Test Prototype Validation

    Vancouver, British Columbia--(Newsfile Corp. - July 6, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce that its exclusive diagnostic partner, 3a-Diagnostics GmbH ("3a"), has confirmed successful function of its novel and proprietary COVID-19 (SARS-CoV-2) RNA probes and its universal coronavirus RNA probes in prototype lateral flow assay (the "LFA") testing. Visual confirmation of test results (probe activation) was observed in five to seven minutes.XPhyto and 3a are...

    2020-07-06 3:05 AM EDT
  • XPhyto Engages Knox Communications Inc. for Investor Relations Services

    Vancouver, British Columbia--(Newsfile Corp. - July 1, 2020) -  XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC PINK: XPHYF) ("XPhyto" or the "Company") is pleased to announce that it has entered into an investor relations consulting agreement (the "Agreement") with Knox Communications Inc. ("KCI") to carryout marketing and investor communication activities for the Company. KCI's founder and principal, Knox Henderson, brings more than 25 years' experience in investor relations, corporate finance and communications for publicly listed companies. He has...

    2020-07-01 1:31 AM EDT
  • XPhyto Therapeutics Corp.: Infectious Disease Oral Screening Test Advancement

    Vancouver, British Columbia--(Newsfile Corp. - June 15, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has successfully incorporated peptide biosensors into its oral dissolvable thin film ("ODF") platform. XPhyto and its diagnostic partner, 3a-Diagnostics GmbH ("3a"), are developing pathogen-specific ODF biosensors for infectious diseases, including pandemic threats."Successful incorporation of 3a's peptide biosensors into Vektor's ODF platform...

    2020-06-15 3:30 AM EDT
  • XPhyto's Diagnostic Partners Receive BMBF Grant for Infectious Disease Screening Tests

    Vancouver, British Columbia--(Newsfile Corp. - June 10, 2020) -  XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce that its diagnostic partner, 3a-Diagnostics GmbH ("3a") and their contract research collaborators, have received a €254,200 grant from the German Federal Ministry of Education and Research ("BMBF"). The BMBF grant is part of the "KMU-innovativ" program for small and medium-sized enterprises that are pioneering innovation and technological progress in Germany. Proceeds of the...

    2020-06-10 3:30 AM EDT
  • RETRANSMISSION: COVID-19 Test and Development Programs Update

    Vancouver, British Columbia--(Newsfile Corp. - March 23, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC PINK: XPHYF) ("XPhyto" or the "Company") is pleased to announce updates to its infectious disease programs, particularly as they relate to the COVID-19 (SARS-CoV-2) pandemic.XPhyto's wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has entered into a binding standstill agreement with a European biotechnology company for development of a low-cost rapid real-time oral pathogen screening platform (the "Platform"). The enzyme-based Platform...

    2020-03-23 3:02 AM EDT
  • XPhyto Announces COVID-19 Test and Development Programs Update

    Vancouver, British Columbia--(Newsfile Corp. - March 20, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce updates to its infectious disease programs, particularly as they relate to the COVID-19 (SARS-CoV-2) pandemic.XPhyto's wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has entered into a binding standstill agreement with a European biotechnology company for development of a low-cost rapid real-time oral pathogen screening platform (the "Platform"). The enzyme-based Platform...

    2020-03-20 4:15 PM EDT
  • XPhyto Therapeutics Epilepsy Treatment Program

    Vancouver, British Columbia--(Newsfile Corp. - March 19, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC: XPHYF) ("XPhyto" or the "Company") is pleased to announce significant progress with respect to development of its cannabidiol ("CBD") based Epilepsy product. Further to the Company's press release dated December 9, 2019, titled "Epilepsy Treatment to be Developed with XPhyto Therapeutics Thin Film Delivery System," and based on recent positive product development results, XPhyto will be advancing the program to clinical studies immediately.In...

    2020-03-19 12:45 PM EDT